Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1993 Mar;37(3):377–383. doi: 10.1128/aac.37.3.377

Discovery and development of new antibiotics: the problem of antibiotic resistance.

L L Silver 1, K A Bostian 1
PMCID: PMC187680  PMID: 8460908

Full text

PDF
382

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arthur M., Courvalin P. Contribution of two different mechanisms to erythromycin resistance in Escherichia coli. Antimicrob Agents Chemother. 1986 Nov;30(5):694–700. doi: 10.1128/aac.30.5.694. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bryan L. E., Bedard J. Impermeability to quinolones in gram-positive and gram-negative bacteria. Eur J Clin Microbiol Infect Dis. 1991 Apr;10(4):232–239. doi: 10.1007/BF01966995. [DOI] [PubMed] [Google Scholar]
  3. Bryan L. E. Two forms of antimicrobial resistance: bacterial persistence and positive function resistance. J Antimicrob Chemother. 1989 Jun;23(6):817–820. doi: 10.1093/jac/23.6.817. [DOI] [PubMed] [Google Scholar]
  4. Bush K. Beta-lactamase inhibitors from laboratory to clinic. Clin Microbiol Rev. 1988 Jan;1(1):109–123. doi: 10.1128/cmr.1.1.109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bush L. M., Calmon J., Johnson C. C. Newer penicillins and beta-lactamase inhibitors. Infect Dis Clin North Am. 1989 Sep;3(3):571–594. [PubMed] [Google Scholar]
  6. Calandra T. Spectrum and treatment of bacterial infections in cancer patients with granulocytopenia. Recent Results Cancer Res. 1991;121:329–336. doi: 10.1007/978-3-642-84138-5_39. [DOI] [PubMed] [Google Scholar]
  7. Cohen S. P., McMurry L. M., Levy S. B. marA locus causes decreased expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli. J Bacteriol. 1988 Dec;170(12):5416–5422. doi: 10.1128/jb.170.12.5416-5422.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Coleman K., Griffin D. R., Page J. W., Upshon P. A. In vitro evaluation of BRL 42715, a novel beta-lactamase inhibitor. Antimicrob Agents Chemother. 1989 Sep;33(9):1580–1587. doi: 10.1128/aac.33.9.1580. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Courvalin P. Plasmid-mediated 4-quinolone resistance: a real or apparent absence? Antimicrob Agents Chemother. 1990 May;34(5):681–684. doi: 10.1128/aac.34.5.681. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Cullen M. E., Wyke A. W., Kuroda R., Fisher L. M. Cloning and characterization of a DNA gyrase A gene from Escherichia coli that confers clinical resistance to 4-quinolones. Antimicrob Agents Chemother. 1989 Jun;33(6):886–894. doi: 10.1128/aac.33.6.886. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Cundliffe E. On the nature of antibiotic binding sites in ribosomes. Biochimie. 1987 Aug;69(8):863–869. doi: 10.1016/0300-9084(87)90213-6. [DOI] [PubMed] [Google Scholar]
  12. Curtis N. A., Eisenstadt R. L., East S. J., Cornford R. J., Walker L. A., White A. J. Iron-regulated outer membrane proteins of Escherichia coli K-12 and mechanism of action of catechol-substituted cephalosporins. Antimicrob Agents Chemother. 1988 Dec;32(12):1879–1886. doi: 10.1128/aac.32.12.1879. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Etienne J., Gerbaud G., Fleurette J., Courvalin P. Characterization of staphylococcal plasmids hybridizing with the fosfomycin resistance gene fosB. FEMS Microbiol Lett. 1991 Nov 1;68(1):119–122. doi: 10.1016/0378-1097(91)90406-z. [DOI] [PubMed] [Google Scholar]
  14. Georgopapadakou N. H., Bertasso A., Chan K. K., Chapman J. S., Cleeland R., Cummings L. M., Dix B. A., Keith D. D. Mode of action of the dual-action cephalosporin Ro 23-9424. Antimicrob Agents Chemother. 1989 Jul;33(7):1067–1071. doi: 10.1128/aac.33.7.1067. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Gocke E. Mechanism of quinolone mutagenicity in bacteria. Mutat Res. 1991 May;248(1):135–143. doi: 10.1016/0027-5107(91)90095-6. [DOI] [PubMed] [Google Scholar]
  16. Grahn E., Holm S. E., Roos K. Penicillin tolerance in beta-streptococci isolated from patients with tonsillitis. Scand J Infect Dis. 1987;19(4):421–426. doi: 10.3109/00365548709021674. [DOI] [PubMed] [Google Scholar]
  17. Grayson M. L., Eliopoulos G. M. Antimicrobial resistance in the intensive care unit. Semin Respir Infect. 1990 Sep;5(3):204–214. [PubMed] [Google Scholar]
  18. Grosh W. W., Quesenberry P. J. Recombinant human hematopoietic growth factors in the treatment of cytopenias. Clin Immunol Immunopathol. 1992 Jan;62(1 Pt 2):S25–S38. doi: 10.1016/0090-1229(92)90038-p. [DOI] [PubMed] [Google Scholar]
  19. Hamilton-Miller J. M. From foreign pharmacopoeias: 'new' antibiotics from old? J Antimicrob Chemother. 1991 Jun;27(6):702–705. doi: 10.1093/jac/27.6.702. [DOI] [PubMed] [Google Scholar]
  20. Hamilton-Miller J. M. The emergence of antibiotic resistance: myths and facts in clinical practice. Intensive Care Med. 1990;16 (Suppl 3):S206–S211. doi: 10.1007/BF01709702. [DOI] [PubMed] [Google Scholar]
  21. Hardisson C., Villar C. J., Llaneza J., Mendoza M. C. Prédominance et dispersion des plasmides conférant la résistance á la fosfomycine chez des entérobactéries. Pathol Biol (Paris) 1984 Sep;32(7):755–758. [PubMed] [Google Scholar]
  22. Hardy D. J., Hensey D. M., Beyer J. M., Vojtko C., McDonald E. J., Fernandes P. B. Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides. Antimicrob Agents Chemother. 1988 Nov;32(11):1710–1719. doi: 10.1128/aac.32.11.1710. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Hooper D. C., Wolfson J. S., Ng E. Y., Swartz M. N. Mechanisms of action of and resistance to ciprofloxacin. Am J Med. 1987 Apr 27;82(4A):12–20. [PubMed] [Google Scholar]
  24. Kobayashi F., Saino Y., Koshi T., Hattori Y., Nakayama M., Iwasaki A., Mori T., Mitsuhashi S. Antimicrobial and beta-lactamase inhibitory activities of carpetimycins A and B, new carbapenem antibiotics. Antimicrob Agents Chemother. 1982 Apr;21(4):536–544. doi: 10.1128/aac.21.4.536. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Kuntz I. D. Structure-based strategies for drug design and discovery. Science. 1992 Aug 21;257(5073):1078–1082. doi: 10.1126/science.257.5073.1078. [DOI] [PubMed] [Google Scholar]
  26. Labia R., Barthélémy M., Péduzzi J., Morand A., Tiwari K., Kazmierczak A. Overcoming enzymatic resistance in bacteria: impact on future therapy. J Int Med Res. 1990;18 (Suppl 4):48D–57D. [PubMed] [Google Scholar]
  27. Larder B. A., Darby G., Richman D. D. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science. 1989 Mar 31;243(4899):1731–1734. doi: 10.1126/science.2467383. [DOI] [PubMed] [Google Scholar]
  28. Larder B. A., Kemp S. D. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science. 1989 Dec 1;246(4934):1155–1158. doi: 10.1126/science.2479983. [DOI] [PubMed] [Google Scholar]
  29. Limb D. I., Dabbs D. J., Spencer R. C. In-vitro selection of bacteria resistant to the 4-quinolone agents. J Antimicrob Chemother. 1987 Jan;19(1):65–71. doi: 10.1093/jac/19.1.65. [DOI] [PubMed] [Google Scholar]
  30. Marr J. J., Moffet H. L., Kunin C. M. Guidelines for improving the use of antimicrobial agents in hospitals: a statement by the Infectious Diseases Society of America. J Infect Dis. 1988 May;157(5):869–876. doi: 10.1093/infdis/157.5.869. [DOI] [PubMed] [Google Scholar]
  31. McMurry L. M., Cullinane J. C., Levy S. B. Transport of the lipophilic analog minocycline differs from that of tetracycline in susceptible and resistant Escherichia coli strains. Antimicrob Agents Chemother. 1982 Nov;22(5):791–799. doi: 10.1128/aac.22.5.791. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Mendoza M. C., Teran F. J., Mendez F. J., Hardisson C. Molecular relationship among fosfomycin-resistant plasmids and clinical impact of fosfomycin resistance. Microbiologica. 1988 Oct;11(4):289–297. [PubMed] [Google Scholar]
  33. Mitsuya H., Yarchoan R., Kageyama S., Broder S. Targeted therapy of human immunodeficiency virus-related disease. FASEB J. 1991 Jul;5(10):2369–2381. doi: 10.1096/fasebj.5.10.1712326. [DOI] [PubMed] [Google Scholar]
  34. Neu H. C. Fosfomycin trometamol versus amoxycillin--single-dose multicenter study of urinary tract infections. Chemotherapy. 1990;36 (Suppl 1):19–23. doi: 10.1159/000238810. [DOI] [PubMed] [Google Scholar]
  35. Nikaido H. Bacterial resistance to antibiotics as a function of outer membrane permeability. J Antimicrob Chemother. 1988 Jul;22 (Suppl A):17–22. doi: 10.1093/jac/22.supplement_a.17. [DOI] [PubMed] [Google Scholar]
  36. Nikaido H., Rosenberg E. Y. Cir and Fiu proteins in the outer membrane of Escherichia coli catalyze transport of monomeric catechols: study with beta-lactam antibiotics containing catechol and analogous groups. J Bacteriol. 1990 Mar;172(3):1361–1367. doi: 10.1128/jb.172.3.1361-1367.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Parry M. F. Epidemiology and mechanisms of antimicrobial resistance. Am J Infect Control. 1989 Oct;17(5):286–294. doi: 10.1016/0196-6553(89)90185-5. [DOI] [PubMed] [Google Scholar]
  38. Shen L. L., Mitscher L. A., Sharma P. N., O'Donnell T. J., Chu D. W., Cooper C. S., Rosen T., Pernet A. G. Mechanism of inhibition of DNA gyrase by quinolone antibacterials: a cooperative drug--DNA binding model. Biochemistry. 1989 May 2;28(9):3886–3894. doi: 10.1021/bi00435a039. [DOI] [PubMed] [Google Scholar]
  39. Silley P., Griffiths J. W., Monsey D., Harris A. M. Mode of action of GR69153, a novel catechol-substituted cephalosporin, and its interaction with the tonB-dependent iron transport system. Antimicrob Agents Chemother. 1990 Sep;34(9):1806–1808. doi: 10.1128/aac.34.9.1806. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Silver L., Bostian K. Screening of natural products for antimicrobial agents. Eur J Clin Microbiol Infect Dis. 1990 Jul;9(7):455–461. doi: 10.1007/BF01964283. [DOI] [PubMed] [Google Scholar]
  41. Smith D. R., Calvo J. M. Nucleotide sequence of dihydrofolate reductase genes from trimethoprim-resistant mutants of Escherichia coli. Evidence that dihydrofolate reductase interacts with another essential gene product. Mol Gen Genet. 1982;187(1):72–78. doi: 10.1007/BF00384386. [DOI] [PubMed] [Google Scholar]
  42. Steinbrecher U. P. Serious infection in an adult due to penicillin-tolerant group B streptococcus. Arch Intern Med. 1981 Nov;141(12):1714–1715. [PubMed] [Google Scholar]
  43. Venkateswaran P. S., Wu H. C. Isolation and characterization of a phosphonomycin-resistant mutant of Escherichia coli K-12. J Bacteriol. 1972 Jun;110(3):935–944. doi: 10.1128/jb.110.3.935-944.1972. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Weisblum B. Inducible resistance to macrolides, lincosamides and streptogramin type B antibiotics: the resistance phenotype, its biological diversity, and structural elements that regulate expression--a review. J Antimicrob Chemother. 1985 Jul;16 (Suppl A):63–90. doi: 10.1093/jac/16.suppl_a.63. [DOI] [PubMed] [Google Scholar]
  45. Wise R., Andrews J. M. In vitro activity of fludalanine combined with pentizidone compared with those of other agents. Antimicrob Agents Chemother. 1984 May;25(5):612–617. doi: 10.1128/aac.25.5.612. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Wolfson J. S., Hooper D. C. Bacterial resistance to quinolones: mechanisms and clinical importance. Rev Infect Dis. 1989 Jul-Aug;11 (Suppl 5):S960–S968. doi: 10.1093/clinids/11.supplement_5.s960. [DOI] [PubMed] [Google Scholar]
  47. Wolfson J. S., Hooper D. C. Fluoroquinolone antimicrobial agents. Clin Microbiol Rev. 1989 Oct;2(4):378–424. doi: 10.1128/cmr.2.4.378. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Wright G. E., Gambino J. J. Quantitative structure-activity relationships of 6-anilinouracils as inhibitors of Bacillus subtilis DNA polymerase III. J Med Chem. 1984 Feb;27(2):181–185. doi: 10.1021/jm00368a013. [DOI] [PubMed] [Google Scholar]
  49. Yoshida T., Kazuno Y., Shomura T., Murata S., Inouye S., Ito T. Therapeutic effect of SF-2103A, a novel carbapenem antibiotic, in combination with cefotaxime, cefoperazone and other cephalosporins. J Antibiot (Tokyo) 1986 Jul;39(7):956–965. doi: 10.7164/antibiotics.39.956. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES